Qiming Venture Partners

Activity in this selectionApr 30, 2026 · Apr 1, 2026

By stage

Undisclosed3

Series A2

Series B1

Biotech4

Healthtech2

China6

6 in this selection

Apr 29

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

$50MSeries A+

Role not disclosed

Apr 19

Develops interventional therapies for pulmonary hypertension and heart failure

$100MStrategic

Role not disclosed

Apr 10

Develops extrahepatic RNA-targeting therapeutics

$54MSeries A

Role not disclosed

Apr 9

Develops next-generation cell therapies for oncology and immunology

$110MPre-IPO

Role not disclosed

Apr 3

Develops intelligent platform-driven macrocyclic peptide drug discovery

$150MSeries B

Role not disclosed

Apr 2

Develops minimally invasive implantable brain-machine interfaces (BMI) for neurological diseases

CN¥500MStrategic

Role not disclosed